Abstract 429: Integrated genomic DNA and RNA profiling to predict cancer immunotherapy response

Abstract

Abstract Immunotherapy response varies widely, making it difficult for physicians to know whether immunotherapy will be effective for a given patient. Recent studies have reported that patients with high PD-L1 gene expression are likely to respond to checkpoint blocking drugs, but there are still many patients whose tumor test for the PD-L1 protein are negative and can respond to the drugs. In addition to the potential link between mismatch repair (MMR) gene mutations and clinical response to anti-PD1 immunotherapy drug, recent findings show that tumor mutation burden and microsatellite instable (MSI) are good indicators of the cancer immunotherapy responses. Using Predicine’s proprietary Gene RADAR (RNA and DNA single molecular digital Readings) technology, here we report the development of PrediSeq-CI (Cancer Immunotherapy) panel for comprehensive genomic profiling of DNA and RNA that are associated with cancer immunotherapy response. The panel has been tested using both tissue biopsy and plasma samples. The development of PrediSeq-CI test has potential to enable precision medicine in cancer immunotherapy. Finally, we also developed a liquid biopsy droplet digital PCR test to measure PD-L1 expression in blood. Citation Format: Pan Du, Xiaohong Wang, Zhixin Zhao, Huiquang Wang, Shidong Jia. Integrated genomic DNA and RNA profiling to predict cancer immunotherapy response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 429. doi:10.1158/1538-7445.AM2017-429